albendazole has been researched along with Lassitude in 1 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Albendazole is a potential anticancer agent that is currently under development for the treatment of cancer." | 2.75 | Phase I clinical trial to determine maximum tolerated dose of oral albendazole in patients with advanced cancer. ( Chin, M; Galettis, P; Liauw, W; Links, M; Morris, DL; Pourgholami, MH; Seef, J; Szwajcer, M, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pourgholami, MH | 1 |
| Szwajcer, M | 1 |
| Chin, M | 1 |
| Liauw, W | 1 |
| Seef, J | 1 |
| Galettis, P | 1 |
| Morris, DL | 1 |
| Links, M | 1 |
1 trial available for albendazole and Lassitude
| Article | Year |
|---|---|
Phase I clinical trial to determine maximum tolerated dose of oral albendazole in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Albendazole; Antineoplastic Agents; Area Under | 2010 |